Opko Health (NASDAQ:OPK) posted its quarterly earnings results on Friday. The biotechnology company reported ($0.05) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.03, Briefing.com reports. Opko Health had a negative return on equity of 9.32% and a negative net margin of 31.73%. The company had revenue of $250.00 million for the quarter, compared to analysts’ expectations of $264.04 million. During the same period in the previous year, the firm earned ($0.08) EPS. The firm’s revenue was up 1.6% compared to the same quarter last year.
Shares of OPK traded down $0.40 during mid-day trading on Friday, hitting $3.09. 7,341,070 shares of the stock were exchanged, compared to its average volume of 3,831,201. The stock has a market capitalization of $2.16 billion, a price-to-earnings ratio of -10.66 and a beta of 1.89. Opko Health has a 52-week low of $2.66 and a 52-week high of $6.40. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.05 and a quick ratio of 0.90.
In other news, CEO Phillip Md Et Al Frost acquired 5,000 shares of the firm’s stock in a transaction dated Tuesday, August 28th. The shares were acquired at an average cost of $5.80 per share, with a total value of $29,000.00. Following the acquisition, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at $17,799,915.80. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders have bought a total of 70,000 shares of company stock worth $392,950 over the last ninety days. Insiders own 42.74% of the company’s stock.
About Opko Health
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.
Featured Story: Swap
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.